Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases

被引：10
作者：
Ait-Oufella, Hafid [1 ,2 ]
Libby, Peter [3 ]
Tedgui, Alain [1 ]
机构：
[1] Univ Paris, Paris Cardiovasc Res Ctr, INSERM, U970, Paris, France
[2] Sorbonne Univ, Hop St Antoine, AP HP, Serv Reanimat Med, Paris, France
[3] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
ARCHIVES OF CARDIOVASCULAR DISEASES | 2020年 / 113卷 / 01期
关键词：
Cytokines; Immunotherapy; Monoclonal antibody; Atherosclerosis; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; SECUKINUMAB; SAFETY;
D O I：
10.1016/j.acvd.2019.11.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：5 / 8
页数：4
相关论文
共 15 条
  • [1] Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk
    Ait-Oufella, Hafid
    Libby, Peter
    Tedgui, Alain
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (08) : 1510 - 1519
  • [2] Recent Advances on the Role of Cytokines in Atherosclerosis
    Ait-Oufella, Hafid
    Taleb, Soraya
    Mallat, Ziad
    Tedgui, Alain
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (05) : 969 - 979
  • [3] Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
    Chung, ES
    Packer, M
    Lo, KH
    Fasanmade, AA
    Willerson, JT
    [J]. CIRCULATION, 2003, 107 (25) : 3133 - 3140
  • [4] Carotid Intima-Media Thickness in Psoriatic Arthritis Differences Between Tumor Necrosis Factor-α Blockers and Traditional Disease-Modifying Antirheumatic Drugs
    Di Minno, Matteo Nicola Dario
    Iervolino, Salvatore
    Peluso, Rosario
    Scarpa, Raffaele
    Di Minno, Giovanni
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (03) : 705 - 712
  • [5] Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study
    Kim, Seoyoung C.
    Solomon, Daniel H.
    Rogers, James R.
    Gale, Sara
    Klearman, Micki
    Sarsour, Khaled
    Schneeweiss, Sebastian
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (06) : 1154 - 1164
  • [6] All roads lead to IL-6: A central hub of cardiometabolic signaling
    Libby, Peter
    Rocha, Viviane Zorzanelli
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 259 : 213 - 215
  • [7] Inflammation and Immunity in Diseases of the Arterial Tree Players and Layers
    Libby, Peter
    Hansson, Goran K.
    [J]. CIRCULATION RESEARCH, 2015, 116 (02) : 307 - 311
  • [8] Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
    Mease, Philip J.
    McInnes, Iain B.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Rahman, Proton
    van der Heijde, Desiree
    Landewe, Robert
    Nash, Peter
    Pricop, Luminita
    Yuan, Jiacheng
    Richards, Hanno B.
    Mpofu, Shephard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (14) : 1329 - 1339
  • [9] Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
    Papp, K. A.
    Langley, R. G.
    Sigurgeirsson, B.
    Abe, M.
    Baker, D. R.
    Konno, P.
    Haemmerle, S.
    Thurston, H. J.
    Papavassilis, C.
    Richards, H. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 412 - 421
  • [10] Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
    Ridker, Paul M.
    Libby, Peter
    MacFadyen, Jean G.
    Thuren, Tom
    Bauantyne, Christie
    Fonseca, Francisco
    Koenig, Wolfgang
    Shimokawa, Hiroaki
    Everett, Brendan M.
    Glynn, Robert J.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (38) : 3499 - 3507
12